Altfest L J & Co. Inc. Raises Position in Eli Lilly and Company (LLY)
Altfest L J & Co. Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 140.7% during the second quarter, Holdings Channel reports. The firm owned 16,848 shares of the company’s stock after buying an additional 9,848 shares during the period. Altfest L J & Co. Inc.’s holdings in Eli Lilly and were worth $1,387,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. Joel Isaacson & Co. LLC raised its stake in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the period. Nisa Investment Advisors LLC raised its stake in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the period. Washington Trust Bank raised its stake in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the period. Bollard Group LLC raised its stake in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the period. Finally, Sabal Trust CO raised its stake in Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock valued at $538,000 after buying an additional 75 shares during the period. 75.61% of the stock is currently owned by institutional investors.
Eli Lilly and Company (LLY) traded down 0.47% during trading on Friday, hitting $81.15. The stock had a trading volume of 2,446,392 shares. The firm has a market cap of $85.61 billion, a price-to-earnings ratio of 35.11 and a beta of 0.34. The firm’s 50 day moving average is $82.91 and its 200 day moving average is $81.72. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the previous year, the company posted $0.86 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/13/altfest-l-j-co-inc-raises-position-in-eli-lilly-and-company-lly.html.
Several analysts have weighed in on LLY shares. BMO Capital Markets set a $71.00 target price on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a report on Monday, July 17th. Credit Suisse Group reissued an “outperform” rating and issued a $87.00 target price on shares of Eli Lilly and in a report on Wednesday, April 19th. Jefferies Group LLC reissued a “buy” rating and issued a $92.00 target price (down previously from $94.00) on shares of Eli Lilly and in a report on Saturday, April 29th. Finally, Berenberg Bank reissued a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and has an average rating of “Hold” and an average target price of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock worth $55,845,287 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.